Macrocycles are complex compounds that can interact with targets that are often unreachable with traditional small molecules. Orbis Medicines is addressing the challenge with its nCycles, synthetic macrocycle drugs that are orally available but hit targets that would otherwise require biologic therapies. We spoke to Morten Graugaard, CEO of Orbis Medicines, about its class of synthetic macrocycles called nCycles, its platform technology to generate and screen these therapies, and how they can offer an orally-delivered alternative to biologics.
